China Drug Delivery Devices Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Historical Data Period | 2019 - 2022 |
| CAGR (2024 - 2029) | 9.21 % |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
China Drug Delivery Devices Market Analysis
The China Drug Delivery Devices Market is expected to register a CAGR of 9.21% during the forecast period.
The major factors contributing to the growth of the Chinese drug delivery devices market are the growing burden of chronic diseases such as cerebrovascular diseases, cancer, chronic respiratory diseases, and diabetes, as well as the technological advancements in drug delivery devices. Due to the rising burden of chronic diseases, drug delivery systems are being frequently used to enhance patient health and treatment outcomes. For instance, as per the data published by the International Agency for Research on Cancer in February 2024, the estimated number of new cancer cases in China was 4.82 million in 2022, which is expected to reach 5.13 million by 2025. There is a gradual rise in the incidence of cancer in China, which is expected to increase demand for delivery devices such as prefilled syringes and autoinjectors during the forecast period.
Furthermore, training on drug delivery device usage is expected to increase the use of these devices in hospitals, which is expected to drive market growth over the forecast period. For instance, in August 2023, Dongguan Songshan Lake Donghua Hospital stated that it had started a new technology training course for upper arm implantable drug delivery devices in Dongguan. This initiative is expected to increase the number of trained staff in hospitals, which may increase the usage of these devices and boost market growth over the forecast period.
The strategic activities of the market players, such as product launches, mergers and acquisitions, and partnerships, are expected to boost the market's growth over the forecast period. For instance, in January 2024, Suzhou Saiwei Biotechnology Co. Ltd signed a strategic cooperation agreement with Borri Pharmaceuticals. With this agreement, the two companies cooperate on the production and supply of automatic injection pens, which is expected to increase the availability of these drug delivery devices, thereby boosting the market growth over the forecast period.
Thus, all the factors above, such as the rising prevalence of chronic diseases and strategic activities by market players, are expected to boost the market growth over the forecast period. However, the high development cost for drug delivery devices is expected to restrain market growth over the forecast period.
China Drug Delivery Devices Market Trends
The Autoinjectors Segment is Expected to Hold Significant Market Share Over the Forecast Period
The autoinjectors segment is expected to grow significantly due to increasing technological advancements, collaborations, and partnerships among companies for autoinjectors and the increased burden of chronic diseases. For instance, in January 2023, Yuanda Pharmaceuticals stated that its innovative products achieved phased results of the Jext prefilled epinephrine autoinjector pen for treating severe allergic reactions and received approval in the Greater Bay, China. These new product approvals may increase the availability and usage of autoinjectors in China, which is expected to boost the segment growth over the forecast period.
Furthermore, the high burden of cardiovascular diseases, such as coronary heart disease and stroke, is expected to increase drug treatments that can be delivered using autoinjector devices. For instance, the China Cardiovascular Health and Disease Report 2022, published in June 2023, reported 330 million cardiovascular diseases, which include 13 million strokes, 11.39 million coronary heart disease, 8.9 million heart failure, and 245 million hypertension cases in 2022. This shows the high burden of cardiovascular diseases, which is expected to boost the usage of autoinjector devices for drug delivery in treatment, increasing the segment growth over the study period.
Thus, due to the factors mentioned above, such as the high burden of chronic diseases and product approvals, the autoinjectors segment is expected to grow significantly during the forecast period.
The Pulmonary Disease Segment is Expected to Hold the Significant Market Share During the Forecast Period
Pulmonary disease is a type of disease that affects the lungs and other parts of the respiratory system. Pulmonary diseases can be caused by infection, smoking tobacco, or breathing in second-hand tobacco smoke, radon, asbestos, or other forms of air pollution. Some of the most common pulmonary diseases are chronic obstructive pulmonary disease (COPD), occupational lung diseases, asthma, and pulmonary hypertension. Pulmonary drug devices help inhale through the mouth and deposit it in the lower airways. The pulmonary diseases segment is expected to hold a significant market share owing to the rise in prevalence of this disease in the country and the demand for drug-delivery devices.
According to the study published in Value in Health Regional Issues in November 2022, between 2020 and 2039, China was expected to experience a rise in the number of COPD patients from 88.3 million to 103.3 million, accompanied by a 31% rise in severe cases. Thus, the significant burden of COPD in the country is expected to propel the segment's growth over the forecast period.
The market player strategies, such as product approvals and launches, are expected to boost the segment growth. For instance, in November 2023, Nanchang Baiji Medicine Technology Co. Ltd obtained the approval of the National Medical Products Administration (NMPA) for the budesonide nasal spray. Hence, these approvals increase the availability of drug-delivery devices for respiratory diseases, which is expected to drive the segment growth over the forecast period.
China Drug Delivery Devices Industry Overview
The Chinese drug delivery devices market is highly competitive and consists of several key players. In terms of market share, a few of the major players are currently dominating the market, and some prominent players are vigorously making acquisitions and joint ventures with other companies to consolidate their market positions in the country. Some of the key players include Gerresheimer AG, Pfizer Inc., F. Hoffmann-La Roche AG, Becton, Dickinson and Company, Teva Pharmaceutical Industries Ltd, Merck & Co. Inc., Novartis AG, Sanofi, GSK PLC, and Baxter.
China Drug Delivery Devices Market Leaders
-
Becton, Dickinson and Company
-
Gerresheimer AG
-
Pfizer Inc.
-
Teva Pharmaceutical Industries Ltd
-
Teleflex Medical
*Disclaimer: Major Players sorted in no particular order
China Drug Delivery Devices Market News
- May 2024: Iconovo AB received approval from the Chinese Patent Office for a patent for the inhalation platform ICOres. With this, Iconovo is expected to receive patent protection for the inhaler in China until 2040 after a series of administrative steps.
- April 2024: Aptar Pharma received approval from the National Medical Products Administration (NMPA) in China for Sinomune Pharmaceutical’s Li Fu metronidazole gel. This drug is used to treat papulopustular rosacea, and Aptar Pharma’s Mezzo+ CS Airless dispensing solution is used for dermal drug delivery.
China Drug Delivery Devices Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Increasing Prevalence of Chronic Diseases
- 4.2.2 Advancement in Technology
-
4.3 Market Restraints
- 4.3.1 The High Cost of Development
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
-
5.1 By Device Type
- 5.1.1 Nasal
- 5.1.1.1 Inhalers
- 5.1.1.2 Other Device Types
- 5.1.2 Implantable
- 5.1.3 Injectable
- 5.1.3.1 Conventional Drug Delivery Devices
- 5.1.3.2 Self-injectable Drug Delivery Devices
- 5.1.3.2.1 Prefilled Syringes
- 5.1.3.2.2 Auto-Injectors
- 5.1.3.2.3 Other Self-injectable Drug Delivery Devices
- 5.1.4 Other Device Types
-
5.2 By Therapeutic Application
- 5.2.1 Cardiovascular
- 5.2.2 Oncology
- 5.2.3 Autoimmune Disorder
- 5.2.4 Pulmonary Disease
- 5.2.5 Other Therapeutic Applications
-
5.3 By Sales Channel
- 5.3.1 Hospitals
- 5.3.2 Pharmacy
- 5.3.3 Other Sales Channels
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Gerresheimer AG
- 6.1.2 Pfizer Inc.
- 6.1.3 Teleflex Medical
- 6.1.4 Becton, Dickinson and Company
- 6.1.5 Teva Pharmaceutical Industries Ltd
- 6.1.6 Merck & Co. Inc.
- 6.1.7 Novartis AG
- 6.1.8 Biocorp
- 6.1.9 GSK PLC
- 6.1.10 Baxter
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityChina Drug Delivery Devices Industry Overview
As per the scope of the report, drug delivery devices are specialized tools for delivering a drug or therapeutic agent via a specific route of administration.
The Chinese drug delivery devices market is segmented by device type, therapeutic application, and sales channel. By device type, the market is segmented into nasal, implantable, injectable, and other device types. The nasal segment includes inhalers and other device types. The injectable segment includes conventional drug delivery devices and self-injectable drug delivery devices. Self-injectable drug delivery devices include prefilled syringes, auto-injectors, and other self-injectable drug delivery devices. The other device types include droppers and sprays. By therapeutic application, the market is segmented into cardiovascular, oncology, autoimmune disorder, pulmonary disease, and other therapeutic applications. Other therapeutic applications include metabolic diseases, infectious diseases, and others. By sales channel, the market is segmented into hospitals, pharmacies, and other sales channels. The other sales channels include clinics, ambulatory centers, and others. The report offers market sizes and forecasts in terms of value (USD) for the above segments.
| By Device Type | Nasal | Inhalers | |
| Other Device Types | |||
| By Device Type | Implantable | ||
| Injectable | Conventional Drug Delivery Devices | ||
| Self-injectable Drug Delivery Devices | Prefilled Syringes | ||
| Auto-Injectors | |||
| Other Self-injectable Drug Delivery Devices | |||
| Other Device Types | |||
| By Therapeutic Application | Cardiovascular | ||
| Oncology | |||
| Autoimmune Disorder | |||
| Pulmonary Disease | |||
| Other Therapeutic Applications | |||
| By Sales Channel | Hospitals | ||
| Pharmacy | |||
| Other Sales Channels |
China Drug Delivery Devices Market Research FAQs
What is the current China Drug Delivery Devices Market size?
The China Drug Delivery Devices Market is projected to register a CAGR of 9.21% during the forecast period (2024-2029)
Who are the key players in China Drug Delivery Devices Market?
Becton, Dickinson and Company, Gerresheimer AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd and Teleflex Medical are the major companies operating in the China Drug Delivery Devices Market.
What years does this China Drug Delivery Devices Market cover?
The report covers the China Drug Delivery Devices Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the China Drug Delivery Devices Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
China Drug Delivery Devices Industry Report
Statistics for the 2024 China Drug Delivery Devices market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. China Drug Delivery Devices analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
